Skip Navigation


NDT Advance Access originally published online on April 5, 2006
Nephrology Dialysis Transplantation 2006 21(8):2263-2269; doi:10.1093/ndt/gfl132
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/8/2263    most recent
gfl132v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hartog, J. W. L.
Right arrow Articles by Smit, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hartog, J. W. L.
Right arrow Articles by Smit, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Original Articles: Dialysis and Transplantation

Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients

Jasper W. L. Hartog1,2, Aiko P. J. de Vries1,2, Stephan J. L. Bakker1,3, Reindert Graaff4, Willem J. van Son2, Jaap J. Homan van der Heide2, Reinold O. B. Gans1, Bruce H. R. Wolffenbuttel5, Paul E. de Jong2 and Andries J. Smit1

1 Department of Medicine, 2 Division of Nephrology, 3 Department of Clinical Pharmacology, 4 Department of Biomedical Engineering and 5 Division of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Correspondence and offprint requests to: Jasper W. L. Hartog, MD, University Medical Center Groningen, University of Groningen, Department of Medicine, Division of Nephrology, PO Box 30 001, 9700 RB Groningen, The Netherlands. Email: j.w.l.hartog{at}int.umcg.nl

Background. Accumulation of advanced glycation end-products (AGEs) has been implicated in the pathogenesis of chronic transplant dysfunction and cardiovascular disease in renal transplant recipients. We aimed to investigate which factors are associated with tissue AGE accumulation in renal transplant recipients.

Methods. The AGE accumulation was assessed using a validated skin-autofluorescence reader (AFR) in 285 consecutive renal transplant recipients (57% male, aged 50±12 years) visiting the outpatient clinic at a median (interquartile range) time of 73 (32–143) months after transplantation. Furthermore, various transplant- and recipient-related factors of interest were collected.

Results. Average skin-autofluorescence of lower arm and leg was 2.7±0.8 a.u. Skin-autofluorescence was positively determined by recipient age, systolic blood pressure, smoking, high-sensitivity C-reactive protein, duration of pre-transplant dialysis, and negatively by plasma vitamin C levels, creatinine clearance at baseline, and change in creatinine clearance since one year after transplantation in linear multivariate regression analysis. Together, these factors explained 41% of the variance of skin-autofluorescence.

Conclusions. Skin-autofluorescence was associated with several risk factors for cardiovascular disease and chronic renal transplant dysfunction. These results are in line with the hypothesis that AGEs play a role in the pathogenesis of these conditions in renal transplant recipients. Prospective studies are required to investigate whether the AFR can be used as a simple, non-invasive tool to identify and monitor patients at risk for chronic renal transplant dysfunction and cardiovascular disease.

Keywords: advanced glycation end-products; cardiovascular disease; chronic renal transplant dysfunction; renal transplantation; risk factors; skin-autofluorescence


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
H. L. Nienhuis, K. de Leeuw, J. Bijzet, A. Smit, C. G. Schalkwijk, R. Graaff, C. G. Kallenberg, and M. Bijl
Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts
Rheumatology, August 13, 2008; (2008) ken302v1.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
A. C. Shirali and M. J. Bia
Management of Cardiovascular Disease in Renal Transplant Recipients
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 491 - 504.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Waanders, E. van den Berg, R. Nagai, I. van Veen, G. Navis, and H. van Goor
Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats
Nephrol. Dial. Transplant., February 1, 2008; 23(2): 518 - 524.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
K. de Leeuw, R. Graaff, R. de Vries, R. P. Dullaart, A. J. Smit, C. G. Kallenberg, and M. Bijl
Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus
Rheumatology, October 1, 2007; 46(10): 1551 - 1556.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.